Prescription medications, including opioid analgesics, are increasingly prescribed in Australia and internationally. More women are presenting in pregnancy with prescription opioid use which can potentially cause harm to the mother and fetus.
Since the 1990s, opioid dispensing in Australia increased from 500 000 prescriptions annually to 7.5 million in 2012 with corresponding increase in governmental cost from $8.5 million to $271 million. 2 These increases in prescribing are at odds with consensus that opioids have limited benefit in the treatment of non-acute pain including chronic non-malignant pain. 3, 4 It is important all health professionals are aware of the potential harms of opioid prescription, including overdose or dependence. Obstetricians and gynaecologists are likely to consult with women who misuse prescription opioids, that is, where medications are used contrary to prescribed directions. In the context of pregnancy, there are additional considerations with exposure of the developing fetus to opioids.
In this article, we outline the different types of prescription opioids, define how prescription opioid use disorder presents clinically and suggest a rational clinical approach to assess and manage patients in the context of pregnancy.
TYPES OF PRESCRIPTION OPIOIDS
Opioids are substances that act on opioid receptors to produce analgesia, respiratory depression, sedation, constipation and euphoric effects. 5 Prescription opioids can be classified into natural, semi-synthetic and synthetic compounds. Morphine and codeine are both prescription opioids that are naturally occurring plant-derived compounds. 6 Semi-synthetic prescription opioids include oxycodone, hydromorphone and buprenorphine. and noradrenaline re-uptake inhibition in the case of tramadol and noradrenaline reuptake inhibition in the case of tapentadol.
Long-acting oxycodone is the most commonly used and prescribed opioid in Australia, whereas in Canada and Germany, the most common are hydromorphone and fentanyl, respectively.
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THE ROLE OF PRESCRIPTION OPIOIDS
Prescription opioid use during pregnancy is increasing. 8, 9 When prescription opioids are required for acute pain management during pregnancy, the selection and dosage of opioids should be tailored to the individual response. Treatment should be started with the lowest effective dose to achieve relief of pain and close monitoring of the patients for response and potential side effects of treatment.
7,9
Opioids should not be considered first-line therapy for patients with chronic noncancer pain. 
ALTERNATIVES TO PRESCRIPTION OPIOIDS DURING PREGNANCY
Paracetamol is usually the first-line analgesia for management of pain in pregnancy. 11 It is a non-opioid analgesic, and although the full mechanism of action is not determined, its analgesic effect may include inhibition of central prostaglandin synthesis and modulation of inhibitory descending serotonergic pathways. At recommended dosages, paracetamol is safe to use in pregnancy. 
12,13
Non-opioid analgesics may offer promising alternatives for pain management. 14 Where chronic pain exists in pregnancy, a collaborative, multidisciplinary team approach that includes obstetrician, psychiatrist, pain specialist, midwife and pharmacist is recommended to provide appropriate treatment and follow-up care in pregnancy.
Antidepressants, anticonvulsants, local anaesthetics and clonidine may be used as analgesic adjuvants in the treatment of neuropathic pain in pregnancy. Amitriptyline 15 and venlafaxine 16 have not been associated with an increased risk of congenital malformations; 17, 18 however, a neonatal withdrawal syndrome may develop due to prenatal exposure, especially in late pregnancy. 18, 19 Due to the possible risk of teratogenic effects and long-term neuropsychological development, sodium valproate, should be avoided in pregnancy. 20, 21 Other anticonvulsants such as gabapentin [22] [23] [24] [25] or pregabalin 26 have shown no sign of teratogenic effect but the decision to treat should be made on an individual basis by considering the risks and benefits to both mother and fetus.
POTENTIAL PROBLEMS WITH OPIOIDS DURING PREGNANCY
There is some evidence to suggest prescription opioid use in the early months of pregnancy may be associated with birth defects, in particular congenital heart defects, neural tube defects, talipes and orofacial clefts. 27 However, most studies are retrospective with the potential for confounding and recall bias. Other studies have found no such associations. 28, 29 Therefore, a detailed anatomical survey by ultrasound should be performed, with particular note of opioid exposure in the pregnancy.
Individuals with a history of addiction or a mental illness are at greater risk of misusing prescription opioids. 30 
APPROACH TO PRESCRIPTION OPIOIDS IN PREGNANCY
It is difficult to ascertain the prevalence of prescription opioid use in pregnancy in Australia. However, all pregnant women taking prescribed opioids should be assessed for dependence (neuroadaptation), risk of withdrawal and potential need for opioid treatment. 31 Opioid dependence can be prevented through a limited timeframe in prescribing for acute pain needs.
Weaning from opioids pre-pregnancy or early in pregnancy may be possible if the woman is assessed as being unlikely to be opioid dependent, the daily dose is not high (less than 60 mg oral morphine equivalent) 4 and if doses are reduced slowly. If the woman has considerable neuro-adaptation it will not be possible to reduce the dose of prescribed opioids due to significant withdrawal symptoms. Neuro-adaptation is more likely if the woman is on a high dose of opioids or if she has been on opioids for a prolonged period (over two to three months). Withdrawal symptoms include myalgias, arthralgias, rhinorrhoea, agitation, abdominal cramping, muscular cramping, restlessness and during pregnancy, threatened preterm labour.
Regular psycho-social support and establishing a therapeutic relationship with a counsellor is needed in many cases to initiate and maintain reductions in taking opioids and include ongoing monitoring of treatment progress.
OPIOID SUBSTITUTION TREATMENT IN PREGNANCY
When neuro-adaptation has occurred, the opioid dose to maintain this state usually increases over the course of the pregnancy.
Reasons for opioid dose increase in pregnancy include the rise in volume of distribution due to increased blood volume, increased metabolism and faster clearance. 32 When pregnant women are taking methadone, methadone plasma levels are significantly lower during the third trimester compared to earlier trimesters, hence the need to increase pharmacotherapy doses. Split-dosing may be advantageous for women on high-dose methadone in the third trimester of pregnancy when metabolism and clearance rates increase and steady-state long-acting opioid levels decline. use simultaneously other opioids. 33 Methadone may be recommended over buprenorphine if high doses are required (>100 mg oral morphine equivalent) as higher therapeutic levels are achievable. 34 The highest dose of buprenorphine is 32 mg daily at which point opioid receptor saturation is likely to have been reached. 34 Buprenorphine formulations can be buprenorphine alone or combined with naloxone. The combination formula was introduced to diminish the likelihood of buprenorphine being injected.
In pregnancy and breastfeeding, the use of buprenorphine only, without naloxone (ie Subutex ® ) is usually advocated.
31
ADVERSE EFFECTS OF PRESCRIPTION OPIOIDS IN PREGNANCY
Some side-effects of prescription opioids are aggravated in pregnancy. Constipation may be exacerbated by the opioid action of slowing gastrointestinal motility. This can result in haemorrhoids, perineal varicosities, rectal pain and bowel obstruction. 35 Overdose resulting in respiratory depression is a real possibility, particularly when opioids are prescribed with other central nervous system depressants (eg diazepam or other benzodiazepines). 36 This respiratory depression can have significant effects on fetal morbidity and mortality.
In the non-pregnant population on methadone, obstructive sleep apnoea is found in up to 35% of patients and is more common in people with a higher body mass index, longer duration in methadone maintenance treatment and non-Caucasian race. 37 These changes may be compounded in pregnancy due the normal physiological changes to sleep reported in the peripartum period.
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Buprenorphine and methadone are listed as Category C drugs. However, neither agent has been linked with teratogenicity or fetal malformations. The provision of methadone along with comprehensive care has been shown to provide far greater benefits than risks.
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OPIOIDS IN THE POSTNATAL PERIOD
Practitioners need to carefully consider discharging women with opioids following birth due to the risk of dependence and the effect these drugs can have on parenting safety. One study 40 in 2017 in the US of 164 720 Medicaid funded women who delivered vaginally, showed that one in ten filled an outpatient prescription for opioids within five days of discharge.
ADVERSE EFFECTS OF OPIOID EXPOSURE ON THE NEONATE
The incidence and severity of neonatal abstinence syndrome and epigenetic mechanisms which impact on maternal drug metabolism, placental transfer and fetal/infant handling can impact NAS development and may, in future, enable more specifically designed mother/infant management. 41, 42 Infants who are exposed to regular opiates predominantly in the last three months of pregnancy whether prescribed or illicit, are at risk of developing drug withdrawal (NAS). NAS manifests following abrupt discontinuation of opioids at birth and indicates the fetus has become neuroadapted in utero. 43 Opioid-exposed infants are assessed from birth for five days for characteristics of NAS using the modified Finnegan scoring Alternate diagnoses which may cause similar signs must always be considered and investigated appropriately, such as infection, hypoglycaemia and hypocalcaemia. 45 Supportive treatment involves non-pharmacological therapy such as a quiet environment, a pacifier, wrapping and cuddling. Pharmacologic treatment commences when the severity of symptoms on the modified Finnegan scoring system reaches a recognised level to commence medication. The scoring system is used to initiate, adjust and wean pharmacological therapy. 43 Opioid treatment for opioid withdrawal is the preferred treatment based on the current literature, 45, 46 usually in the form of oral morphine. In severe cases, concurrent sedation may be indicated where phenobarbital or clonidine is recommended. 43, 47 While most infants exposed to opioids in pregnancy display some signs of NAS, the incidence of those requiring pharmacological treatment ranges from 2.6 to 16.2/1000 births. 48 Involvement of child protection services should be assessed on an individual basis depending on whether the aberrant use of prescription opioids raises concern about the welfare, potential neglect or lack of safety of the infant.
Maternal medication with methadone or buprenorphine is not a contraindication to breast feeding. Breastfeeding advice should reflect consideration of all maternal medications and substance use as well as the benefits of breast feeding for mother and infant.
CONCLUSION
Obstetricians and other health professionals need to be aware of the potential harms of prescription opioids. A holistic approach including interdisciplinary cooperation is imperative to addressing the abuse of these medications. Women planning pregnancy need to be educated about the appropriate use and potential harms of prescription opioids. Ongoing unwanted side effects of long-term opioids should be monitored for and addressed promptly as they arise.
Opioids should not be first-line analgesics but when indicated can be very effective for short-term management of pain.
Opioids in pregnancy bring specific issues for consideration including increasing dose requirements and potential for NAS in the newborn.
Health professionals need to be aware of the escalating harm of prescription opioids in the community, and be able to respond appropriately to curb this preventable cause of death and disability.
